Scarica l'app Stockscreener
0.688
14.00%
-0.112
Dopo l'orario di chiusura:
.73
0.042
+6.10%
Precedente Chiudi:
$0.80
Aprire:
$0.7925
Volume 24 ore:
889.14K
Relative Volume:
1.50
Capitalizzazione di mercato:
$19.26M
Reddito:
-
Utile/perdita netta:
$-75.80M
Rapporto P/E:
-0.1496
EPS:
-4.6004
Flusso di cassa netto:
$-77.17M
1 W Prestazione:
-38.02%
1M Prestazione:
-49.04%
6M Prestazione:
-71.57%
1 anno Prestazione:
-83.74%
Intervallo 1D:
$0.686
$0.811
Intervallo di 1 settimana:
$0.686
$1.12
Portata 52W:
$0.686
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.688 | 19.26M | 0 | -75.80M | -77.17M | -4.6004 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Ripresa | UBS | Neutral |
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks
Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Canada
Citizens reiterates Jasper Therapeutics stock rating on CEO change - Investing.com
JSPR Stock Price, Quote & Chart | JASPER THERAPEUTICS INC (NASDAQ:JSPR) - ChartMill
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - TipRanks
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Jasper Therapeutics stock gains 5% on clinical progress despite Q4 loss - Investing.com
MINISO Group Holding Limited (MNSO) Reports Q4 Earnings - news.alphastreet.com
Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings - news.alphastreet.com
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - Bitget
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c) - TipRanks
Jasper Therapeutics (JSPR) 10-K focuses on briquilimab mast cell programs and funding needs - Stock Titan
JSPR: Strong clinical progress but increased net loss and lower cash reserves highlight funding needs - TradingView
Jasper Therapeutics (NASDAQ: JSPR) posts $75.8M 2025 loss, cash at $28.7M - Stock Titan
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Jasper Therapeutics 4Q Loss $9.1M >JSPR - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Jasper targets late-2026 trial after 75% disease-control data - Stock Titan
Jasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92 - MSN
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88 - Defense World
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab - Yahoo Finance
10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Jasper Therapeutics Inc (JSPR) Stock News & Articles - 24/7 Wall St.
Jasper Therapeutics stock surges on positive briquilimab trial data amid mast cell therapy race - AD HOC NEWS
UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25 - marketscreener.com
UBS initiates Jasper Therapeutics stock rating at Neutral on competition By Investing.com - Investing.com Canada
UBS initiates Jasper Therapeutics stock rating at Neutral on competition - Investing.com
If You Invested $1,000 in Jasper Therapeutics Inc (JSPR) - Stock Titan
Jasper Therapeutics stock surges on positive briquilimab trial data for mast cell diseases - AD HOC NEWS
JSPR Should I Buy - Intellectia AI
Jasper Therapeutics, Inc. (JSPRW) Competitors - Meyka
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
How Jasper Therapeutics Inc. stock compares to industry benchmarksQuarterly Portfolio Review & Weekly High Return Forecasts - Naître et grandir
Aug Opening: How Jasper Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Snapshot & Pattern Based Trade Signal System - Naître et grandir
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
JSPR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
JSPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Millennium-linked firms report ~5.8% holdings in Jasper Therapeutics (JSPR) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference - GlobeNewswire
Long-Term Investors in shares of Jasper Therapeutics, Inc. - openPR.com
Jasper Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
JSPR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Carlyle group shows 3.8% Jasper Therapeutics (JSPR) ownership stake - Stock Titan
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):